Shmuel Yaccoby

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Title	Professor
Institution	University of Arkansas for Medical Sciences
Department	Internal Med, College of Medicine
Division	Internal Med Hem-Onc
Address	933 Cancer Institute 4104 Outpatient Circle Mail Slot # 776 Little Rock AR 72205
Phone	501-686-8250
vCard	Download vCard

Other Positions


Title	Associate Professor
Institution	University of Arkansas for Medical Sciences
Department	Physiology and Cell Biology, College of Medicine

Research

research activities and funding

BI (YACCOBY, SHMUEL)Nov 6, 2012 BioInvent Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo Role: Principal Investigator

BI-505 ICAM-1 (YACCOBY, SHMUEL)Nov 6, 2012 BioInvent Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo Role: Principal Investigator

R01CA134522 (VAN RHEE, FRITS)Aug 22, 2008 - Jun 30, 2014 NIH/Nat. Cancer Institute Potentiating Natural Killer Cell Anti-Myeloma Effects Role: Co-Investigator

Collaborative Research Agreement (YACCOBY, SHMUEL)Dec 14, 2007 - Dec 13, 2009 Celgene Anti-myeloma efficacy of PDACs/HPP Role: Principal Investigator

CollaborativeResearchAgreement (YACCOBY, SHMUEL)Dec 14, 2007 - Dec 13, 2009 Celgene Anti-myeloma efficacy of PDACs/HPP Role: Principal Investigator

CRA (YACCOBY, SHMUEL)May 17, 2007 - Sep 17, 2008 Vantia Therapeutics Ltd. Anti-myeloma efficacy of FAP inhibitor in ex vivo and in vivo systems for primary myeloma Role: Principal Investigator

36 (YACCOBY, SHMUEL)Mar 1, 2007 - Aug 28, 2008 Multiple Myeloma Research Foundation Targeting Dkk1 in multiple myeloma with humanized andti-DKk1 neutralizing antibody Role: Principal Investigator

36-05 (YACCOBY, SHMUEL)Mar 1, 2007 - Aug 28, 2008 Multiple Myeloma Research Foundation Targeting Dkk1 in multiple myeloma with humanized andti-DKk1 neutralizing antibody Role: Principal Investigator

Velcade, No. 214619 (YACCOBY, SHMUEL)Dec 13, 2006 - Dec 13, 2007 Millennium Pharmaceuticals, Inc. Study of Effect of VELCADE on Osteoblast Activity Role: Principal Investigator

Velcade,No.214619 (YACCOBY, SHMUEL)Dec 13, 2006 - Dec 13, 2007 Millennium Pharmaceuticals, Inc. Study of Effect of VELCADE on Osteoblast Activity Role: Principal Investigator

29 (YACCOBY, SHMUEL)Oct 1, 2006 - Sep 30, 2008 Multiple Myeloma Research Foundation Role of SPRPs in the anti-myeloma response of osteoblasts Role: Principal Investigator

29-06 (YACCOBY, SHMUEL)Oct 1, 2006 - Sep 30, 2008 Multiple Myeloma Research Foundation Role of SPRPs in the anti-myeloma response of osteoblasts Role: Principal Investigator

ImmunoGen (YACCOBY, SHMUEL)Oct 1, 2006 - May 2, 2008 ImmunoGen, Inc. Effect of antiCD56-cytotoxic drug conjugate on myeloma cell growth in the bone marrow microenvironment ex vivo and in vivo Role: Principal Investigator

PT (YACCOBY, SHMUEL)Jul 31, 2006 - Nov 30, 2007 Point Therapeutics, Inc Anti-myeloma efficacy of PT-100 and PT-630 in ex vivo and in vivo systems for primary myeloma Role: Principal Investigator

PT-100/PT-630 (YACCOBY, SHMUEL)Jul 31, 2006 - Nov 30, 2007 Point Therapeutics, Inc Anti-myeloma efficacy of PT-100 and PT-630 in ex vivo and in vivo systems for primary myeloma Role: Principal Investigator

Research Agreement (YACCOBY, SHMUEL)May 31, 2006 - May 31, 2009 ZymoGenetics, Inc Effect of TACI-lg and BAFFR-lg on primary myeloma growth in SCID-hu mice Role: Principal Investigator

ResearchAgreement (YACCOBY, SHMUEL)May 31, 2006 - May 31, 2009 ZymoGenetics, Inc Effect of TACI-lg and BAFFR-lg on primary myeloma growth in SCID-hu mice Role: Principal Investigator

28549 VELCADE CRA (YACCOBY, SHMUEL)Dec 2, 2004 - Nov 30, 2006 Millennium Pharmaceuticals, Inc. Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma Role: Principal Investigator

28549VELCADECRA (YACCOBY, SHMUEL)Dec 2, 2004 - Nov 30, 2006 Millennium Pharmaceuticals, Inc. Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma Role: Principal Investigator

SCID-hu mice ABT-510 (YACCOBY, SHMUEL)Oct 14, 2004 - Sep 30, 2007 Abbott, Inc. Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo Role: Principal Investigator

SCID-humiceABT (YACCOBY, SHMUEL)Oct 14, 2004 - Sep 30, 2007 Abbott, Inc. Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo Role: Principal Investigator

R01CA093897 (YACCOBY, SHMUEL)Dec 1, 2001 - Nov 30, 2012 NIH/Nat. Cancer Institute Myeloma-Microenvironment Interaction Dynamics Role: Principal Investigator

Bibliographic

selected publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.

List All | Timeline

Yaccoby S. Advances in the understanding of myeloma bone disease and tumor growth. Br J Haematol. 2010.
Yaccoby S. Role of proteasome in bone formation and osteoclostogenesis. IBMS Bone Key. 2010; 4:147-55.
Van Rhee F,, Szmania S,, Dillon, M,, Van Abbema A,, Li X,, Stone, M,, Garg TK,, Shi J,, Bost-Moreno AM,, Yun R,, Balasa B,, Ganguly B,, Chao D,, Rice AG,, Zhan F,, Shaughnessy J,, Barlogie B,, Yaccoby S,, Afar DEH. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc3) and bortezomib against multiple myeloma. Mol Cancer Ther. 2010; 2616-2624.
Qiang YW, Kitagawa M, Higashi M, Ishii G, Morimoto C, Harigaya K. Activation of mitogen-activated protein kinase through alpha5/beta1 integrin is required for cell cycle progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp Hematol. 2000; 28(10):1147 - 1157.
Jaccoby S, Pinchasov Y, Snapir N, Robinzon B. Hypothalamic obese, functionally castrated hens are hypersensitive to estrogenic modulation of lipid metabolism. Physiol Behav. 1996; 60(3):913 - 918.
Jaccoby S, Arnon E, Snapir N, Robinzon B. Effects of estradiol and tamoxifen on feeding, fattiness, and some endocrine criteria in hypothalamic obese hens. Pharmacol Biochem Behav. 1995; 50(1):55 - 63.
Jaccoby S, Arnon E, Snapir N, Robinzon B. Effects of bilateral basomedial hypothalamic lesions on feeding, fattiness, and reproductive functions in the White Leghorn hen. Physiol Behav. 1994; 56(5):1081 - 1089.
Jaccoby S, Snapir N, Rozenboim I, Arnon E, Meidan R, Robinzon B. Tamoxifen advances puberty in the White Leghorn hen. Br Poult Sci. 1992; 33(1):101 - 111.

Same Department

Search Department